SCHEMBL29832221

SCHEMBL29832221

CCOC(=O)c1sc(Nc2nc(N3CCC(O)CC3)cc(N3CCC(O)(c4ccccc4)CC3)n2)nc1C

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 6/20 0.78
▸ MAPT P10636 6/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ DHODH Q02127 3/20 0.46
▸ LMNA P02545 2/20 0.45
▸ CASP3 P42574 1/20 0.45
▸ SENP8 Q96LD8 1/20 0.45
▸ SENP7 Q9BQF6 1/20 0.45
▸ SENP6 Q9GZR1 1/20 0.45
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CSNK1D P48730 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL290493 1.00 PDE5A (0.78) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL29831777 0.92 PDE5A (0.75) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL290826 0.92 PDE5A (0.75) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL291639 0.92 PDE5A (0.75) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL29831847 0.92 PDE5A (0.75) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL29408529 0.90 PDE5A (0.69) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL290309 0.90 PDE5A (0.69) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL292064 0.89 PDE5A (0.75) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL29831837 0.89 PDE5A (0.75) PDE5AMAPTNPC1RAB9AHPGD
SCHEMBL6068299 0.88 PDE5A (0.86) PDE5AMAPTNPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 — — EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 — — WO disclosed
CN-115192711-A Use of PDE7 inhibitors for the treatment of movement disorders 奥默罗斯公司 2022-10-18 — — CN disclosed
CN-114984229-A Treatment of addiction and impulse control disorders using PDE7 inhibitors 奥默罗斯公司 2022-09-02 — — CN disclosed
Send feedback